PMA
P020011: VERSANT HCV RNA QUALITATIVE ASSAY
FDA PMA · Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus · Gen-Probe
Key facts
| PMA number | P020011 |
|---|---|
| Trade name | VERSANT HCV RNA QUALITATIVE ASSAY |
| Generic name | Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus |
| Applicant | Gen-Probe |
| Owner/operator | HOLOGIC, INC. |
| Product code | MZP |
| Approval date | Nov 7, 2002 |
| Docket number | 03M-0070 |
| Notice date | Feb 28, 2003 |
| Establishment registration | 2024800 |
| FEI number | 2024800 |
At a glance
- 10–99 Supplements
- Jul 21, 2020 Latest supplement decision
- No Withdrawn
- Yes Summary of safety and effectiveness on file
- None UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: